Figure 7.

Functional Changes after Subretinal Gene Therapy for RPE65-IRD

(A) NIR-FAF, 55°-wide images of the posterior retina of the right eye of the two with RPE65-LCA treated with bilateral subretinal gene therapy (Luxturna, Sparks Therapeutics, Philadelphia, PA, USA). Red line denotes the inferior boundary of a subretinal bleb that contains the treating product, which extends from the superior retina crossing the fovea and into the inferior pericentral retina. (B) Light-adapted achromatic and dark-adapted two-color chromatic static perimetry (showing only responses to a blue 500-nm stimulus) in the patients before (dashed lines) and after (continuous line) gene therapy. Dotted lines define lower limit (mean of 2 SD) of sensitivity in control subjects. S, superior visual field; I, inferior visual field. Horizontal arrows show the improvement in sensitivity supporting a treatment effect.